Jaka jest cena za InNexus Biotechnology, Inc. (IXSBF)

Cena za InNexus Biotechnology, Inc. (IXSBF) wynosi $0.0001

Jaka jest kapitalizacja rynkowa dla InNexus Biotechnology, Inc. (IXSBF)

Kapitalizacja rynkowa dla InNexus Biotechnology, Inc. (IXSBF) wynosi $12.63K

InNexus Biotechnology, Inc. (IXSBF) Cena i Kapitalizacja Rynkowa

InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.

Cena za IXSBF	Aktywa B	Kapitalizacja rynkowa B	Wyniki
$42,633.72 $12.63K	NVDA	$5.383T	+42,633,717,014.12%
$35,031.21 $12.63K	AAPL	$4.423T	+35,031,212,410.79%
$32,948.20 $12.63K	GOOG	$4.160T	+32,948,201,365.76%
$29,011.81 $12.63K	MSFT	$3.663T	+29,011,806,639.53%
$22,897.19 $12.63K	AMZN	$2.891T	+22,897,194,763.39%

Cena za IXSBF

Aktywa B

Kapitalizacja rynkowa B

Wyniki

$42,633.72 $12.63K